Comparison of serum lipid management between elderly and non-elderly patients with and without coronary heart disease (CHD).
Comparison of serum lipid management between elderly and non-elderly patients with and without coronary heart disease (CHD).
复制标题
DOI：
10.1016/j.pmedr.2016.06.006
复制
发表时间：
2016-12
影响因子：
2.8
通讯作者：
Kume N
中科院分区：
文献类型：
--
作者：
Shimizu R;Torii H;Yasuda D;Hiraoka Y;Furukawa Y;Yoshimoto A;Iwakura T;Matsuoka N;Tomii K;Kohara N;Hashida T;Kume N
尚未精确探索≥ 75岁患者的血脂管理。因此，我们比较了有和无冠心病（CHD）的两个年龄组之间的血脂管理。因此，我们回顾性分析了14个月内在内科住院的患者的病历。通过将年龄< 75岁的患者的血脂目标应用于年龄≥ 75岁的患者，探索血脂目标的实现情况。在1988例入组患者中，717例受试者（36.1%）年龄≥ 75岁。其中冠心病患者分别占41.3%和32.4%; ≥ 75岁和< 75岁的高危人群分别占44.2%和41.0%，中危人群分别占14.5%和14.6%。冠心病患者中，年龄≥ 75岁和< 75岁的血清LDL-C目标达成率分别为66.9%和65.0%（p = 0.334）。在高危一级预防中，年龄≥ 75岁和< 75岁的患者中，这些发生率分别为73.5%和63.3%（p = 0.001）。在≥ 75岁和< 75岁的中危人群中，一级预防中的比例分别为77.9%和58.1%（P < 0.001）。在冠心病患者中，≥ 75岁患者的降脂药物订购率（60.1%）显著低于< 75岁患者（73.8%，p < 0.001）。总之，在CHD中，两个年龄组之间的血脂目标实现情况相当，尽管≥ 75岁患者的降脂药物处方频率较低。无冠心病的患者中，年龄≥ 75岁的患者明显优于年龄< 75岁的患者，尽管两个年龄组的降脂药物订购率相当。≥ 75岁与< 75岁冠心病患者血脂达标率相当。≥ 75岁冠心病患者的血脂达标率高于< 75岁非冠心病患者。年龄≥ 75岁的冠心病患者比年龄< 75岁的冠心病患者更少使用降脂药物。在年龄≥ 75岁和< 75岁的无CHD患者中，降脂药物的处方几乎相等。他汀类药物加EPA在≥ 75岁的冠心病患者中的使用频率低于< 75岁的冠心病患者。
Serum lipid management in patients aged ≥ 75 has not been precisely explored. We, therefore, compared the serum lipid management between the two age groups with and without coronary heart disease (CHD). We, therefore, retrospectively reviewed medical charts of patients who were hospitalized in the departments of internal medicine during a period of 14 months. Serum lipid goal attainment was explored by applying the lipid goals for patients aged < 75 to those aged ≥ 75. In 1988 enrolled patients, 717 subjects (36.1%) were aged ≥ 75. Among them, 41.3% and 32.4% of the patients had CHD, 44.2% and 41.0% were primary prevention at high-risk, and 14.5% and 14.6% were primary prevention at moderate-risk in patients aged ≥ 75 and aged < 75, respectively. Serum LDL-C goal achievement rates in CHD were 66.9% and 65.0% in patients aged ≥ 75 and < 75, respectively (p = 0.334). In the primary prevention at high-risk, these rates were 73.5% and 63.3%, in patients aged ≥ 75 and < 75, respectively (p = 0.001). They were 77.9% and 58.1% in primary prevention at moderate-risk aged ≥ 75 and < 75, respectively (p < 0.001). In CHD, lipid-lowering medication subscription rates were significantly lower in patients aged ≥ 75 (60.1%) than those aged < 75 (73.8%, p < 0.001). In conclusion, in CHD, serum lipid goal attainment was comparable between the two age groups although the lipid-lowering drugs were less frequently prescribed in patients aged ≥ 75. Without CHD, it was significantly better in patients aged ≥ 75 than those aged < 75 although the lipid-lowering drug subscription rates were comparable between the two age groups. Serum lipid goal attainment was comparable between patients aged ≥ 75 and < 75 with coronary heart disease (CHD). Serum lipid goal attainment was better in patients aged ≥ 75 than those aged < 75 without CHD. Lipid-lowering medication was less frequently prescribed in patients aged ≥ 75 than those aged < 75 with CHD. Lipid-lowering medication was almost equally prescribed between patients aged ≥ 75 and < 75 without CHD. Statin plus EPA was less frequently prescribed in patients aged ≥ 75 than those aged < 75 with or without CHD.